Hamza Suria
Chief Executive Officer at Trotana, Inc.
Hamza Suria active positions
| Companies | Position | Start | End |
|---|---|---|---|
Trotana, Inc.
 Trotana, Inc. BiotechnologyHealth Technology Trotana, Inc. discovers and develops medicines. The company is based in San Diego, CA. The CEO of the company is Hamza Suria. | Chief Executive Officer | - | - |
Career history of Hamza Suria
Former positions of Hamza Suria
| Companies | Position | Start | End |
|---|---|---|---|
| ANAPTYSBIO, INC. | Director/Board Member | 2011-06-30 | 2022-03-19 |
| Chief Executive Officer | 2011-06-30 | 2022-03-19 | |
| Corporate Officer/Principal | 2008-12-31 | 2011-05-31 | |
| President | 2011-06-30 | 2022-03-19 | |
Viron Therapeutics, Inc.
 Viron Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Viron Therapeutics, Inc. discovers and develops novel therapeutics for inflammatory disorders. Its products include VT-111a, a recombinant protein that functions to reduce monocyte infiltration to sites of viral infection, as well as inhibits cardiovascular damage due to coronary stent placement. The firm also develops VT-310, a glycoprotein for the treatment of cancer, VT-384 that inhibit interferon gamma production, VT-346, a glycoprotein that protects against human TNF-mediated inflammatory signals and VT-214, a chemokine binding protein. The company was founded in 1997 and is headquartered in London, Canada. | Corporate Officer/Principal | - | - |
| Diabetogen Biosciences, Inc. | Corporate Officer/Principal | - | - |
Maxygen, Inc.
 Maxygen, Inc. Miscellaneous Commercial ServicesCommercial Services Maxygen, Inc. is a biotechnology company. It is focused on the potential further development of its MAXY-G34 product, a next-generation pegylated, granulocyte colony stimulating factor, G-CSF, for the treatment of chemotherapy induced neutropenia and acute radiation syndrome. G-CSF is a natural protein that functions by stimulating the body's bone marrow to produce more white blood cells. The company was founded on May 7, 1996 and is headquartered in San Mateo, CA. | Corporate Officer/Principal | - | - |
Training of Hamza Suria
| University of Western Ontario | Graduate Degree |
| Kalamazoo College | Undergraduate Degree |
| Richard Ivey School of Business | Masters Business Admin |
| Mercersburg Academy | Undergraduate Degree |
Statistics
International
| United States | 6 |
| Canada | 4 |
| Hong Kong | 2 |
Operational
| Corporate Officer/Principal | 4 |
| Chief Executive Officer | 2 |
| Undergraduate Degree | 2 |
Sectoral
| Consumer Services | 5 |
| Health Technology | 4 |
| Commercial Services | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Listed companies | 1 |
|---|---|
| ANAPTYSBIO, INC. | Health Technology |
| Private companies | 4 |
|---|---|
Maxygen, Inc.
Maxygen, Inc. Miscellaneous Commercial ServicesCommercial Services Maxygen, Inc. is a biotechnology company. It is focused on the potential further development of its MAXY-G34 product, a next-generation pegylated, granulocyte colony stimulating factor, G-CSF, for the treatment of chemotherapy induced neutropenia and acute radiation syndrome. G-CSF is a natural protein that functions by stimulating the body's bone marrow to produce more white blood cells. The company was founded on May 7, 1996 and is headquartered in San Mateo, CA. | Commercial Services |
| Diabetogen Biosciences, Inc. | |
Viron Therapeutics, Inc.
Viron Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Viron Therapeutics, Inc. discovers and develops novel therapeutics for inflammatory disorders. Its products include VT-111a, a recombinant protein that functions to reduce monocyte infiltration to sites of viral infection, as well as inhibits cardiovascular damage due to coronary stent placement. The firm also develops VT-310, a glycoprotein for the treatment of cancer, VT-384 that inhibit interferon gamma production, VT-346, a glycoprotein that protects against human TNF-mediated inflammatory signals and VT-214, a chemokine binding protein. The company was founded in 1997 and is headquartered in London, Canada. | Health Technology |
Trotana, Inc.
Trotana, Inc. BiotechnologyHealth Technology Trotana, Inc. discovers and develops medicines. The company is based in San Diego, CA. The CEO of the company is Hamza Suria. | Health Technology |
- Stock Market
- Insiders
- Hamza Suria
- Experience
